-
Mashup Score: 38
Tumor-associated macrophages (TAMs) are well known to fuel tumor evolution. Blériot et al. advocate for integrating the time dimension when conceptualizing macrophage diversity in pre-malignancy and cancer and propose the term “PreTAMs” to emphasize their early roles in orchestrating inflammatory responses that often precede, and not just result from, tumor onset.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 125Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization - 15 hour(s) ago
Pronounced necrosis in glioblastomas is accompanied by abundant destabilized microvessels. Wang et al. show that the niche cues from the peri-necrotic regions polarize macrophages toward a hypoxic state, which in turn augments vascular hyperpermeability. Targeting adrenomedullin produced by hypoxic macrophages normalizes tumor neovasculature and improves anti-tumor drug delivery and efficacy.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 37Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes - 19 hour(s) ago
Saliby et al. show that a machine learning approach can accurately classify clear cell renal cell carcinoma (RCC) into distinct molecular subtypes using transcriptomic data. When applied to tumors biospecimens from the JAVELIN Renal 101 (JR101) trial, a benefit is observed with immune checkpoint inhibitor (ICI)-based therapy across all molecular subtypes.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 156
Cancer-associated fibroblasts (CAFs) exhibit spatial and functional diversity. Here, Niu et al. unveil SETD2’s function in lipid metabolism and CAF heterogeneity in pancreatic ductal adenocarcinoma. SETD2 deficiency boosts oxidative phosphorylation activity, prompting lipid-laden CAF formation through BMP2 signaling, offering promising therapeutic avenues in personalized cancer treatment.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 92Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects - 2 day(s) ago
Combined immune checkpoint blockade (ICB) for cancer exhibits good efficacy in a subset of patients but also associates with immune-related adverse events. Xue et al. use an elegant drug screening strategy to identify the antimicrobial drug clofazimine as an agent that both potentiates ICB efficacy and decreases immune-related adverse events.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 191
In this issue of Cancer Cell, Spitzer and colleagues demonstrate the role of IDH inhibitors on IDHmutant gliomas in reducing proliferation and enhancing cell differentiation toward an astrocytic-like state, thus altering neurodevelopmental pathways. Despite clinical promise, unresolved questions regarding mechanisms of action and resistance underline the need for further research for treatment optimization.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 373
Dyikanov et al. developed a machine learning platform that uses a simple blood test to reveal cellular compositions reflective of a person’s immune system. These compositions, delineated into five conserved immunotypes, can reflect a person’s disease status or how someone responds to specific treatments, thus underscoring their potential clinical utility for cancer patients.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 112
Diepstraten et al. demonstrate that p53 enforces apoptosis induced by BH3-mimetic drugs. To boost BH3-mimetic-induced apoptosis in TP53-mutant blood cancers, STING agonists were employed to induce pro-apoptotic BH3-only protein expression in a p53-independent manner. Therefore, BH3-mimetics alongside STING agonists represents a promising new combination therapy for aggressive TP53-mutant blood cancers.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 104Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis - 3 day(s) ago
Gupta et al. track checkpoint inhibitor (CPI)-bound T cells utilizing scRNA-seq and subcellular spatial transcriptomics in blood and intestinal tissue, defining distinct T cell subtypes and tissue niches linked to colitis development. They define the pathogenic cellular microdomains differentiating CPI-colitis from ulcerative colitis (UC).
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 283The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia - 3 day(s) ago
Liu et al. identify a novel feedforward loop between tumor cells and macrophages that promotes muscle wasting. Specifically, tumor-derived CCL2 activates macrophages to facilitate non-autonomous activation of TWEAK in tumor cells via CCL5/p65 signaling, leading to cachexia. Macrophage depletion and TWEAK inhibition represent promising therapeutic targets for pancreatic cancer cachexia.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
A temporal perspective for tumor-associated macrophage identities and functions https://t.co/Bs7fJiSRN5 https://t.co/CINpbgbAkS